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Introduction: Global data sharing is essential. This is the premise of the Academic
Research Organization (ARO) Council, which was initiated in Japan in 2013 and has
since been expanding throughout Asia and into Europe and the United States. The
volume of data is growing exponentially, providing not only challenges but also the
clear opportunity to understand and treat diseases in ways not previously considered.
Harnessing the knowledge within the data in a successful way can provide
researchers and clinicians with new ideas for therapies while avoiding repeats of failed
experiments. This knowledge transfer from research into clinical care is at the heart of
a learning health system.
Methods: The ARO Council wishes to form a worldwide complementary system for
the benefit of all patients and investigators, catalyzing more efficient and innovative
medical research processes. Thus, they have organized Global ARO Network Work-
shops to bring interested parties together, focusing on the aspects necessary to make
such a global effort successful. One such workshop was held in Austin, Texas, in
November 2017. Representatives from Japan, Taiwan, Singapore, Europe, and the
United States reported on their efforts to encourage data sharing and to use research
to inform care through learning health systems.
Results: This experience report summarizes presentations and discussions at the
Global ARO Network Workshop held in November 2017 in Austin, TX, with representa-
tives from Japan, Korea, Singapore, Taiwan, Europe, and the United States. Themes and
recommendations to progress their efforts are explored. Standardization and harmoniza-
tion are at the heart of these discussions to enable data sharing. In addition, the trans-
formation of clinical research processes through disruptive innovation, while ensuring
integrity and ethics, will be key to achieving the ARO Council goal to overcome diseases
such that people not only live longer but also are healthier and happier as they age.- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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Global data sharing is essential. This is the premise of the Aca-
demic Research Organization (ARO) Council, which was initiated
in Japan in 2013. The volume of data is growing exponentially, pro-
viding not only challenges but also the clear opportunity to under-
stand and treat diseases in ways not previously considered.
Harnessing the knowledge within the data in a successful way
can provide researchers and clinicians with new ideas for therapies
while avoiding repeats of failed experiments. In addition to data
sharing, the transformation of clinical research processes through
disruptive innovation, while ensuring integrity and ethics, will be
key to achieving the ARO Council goal to overcome intractable dis-
eases such that people not only live longer but also are healthier
and happier as they age.
Over the past 5 years, the ARO Council has been expanding from
Japan into Asia (adding Singapore, Taiwan, and Korea) and now
includes leaders from academic institutions in Europe and the United
States. The establishment of Japan's Agency for Medical Research
and Development (AMED) in 2015 provided a new infrastructure for
innovation and encouragement for the ARO Council. Annual Global
ARO Workshops have taken place with themes focusing on standard-
ization and harmonization of clinical research, a new paradigm of
medical science based upon data sharing, and real‐world data (RWD)
and disruptive innovation. The goal is to form a worldwide
complementary system for the benefit of all patients and investigators,
catalyzing more efficient and innovative medical research processes.
Standardization and harmonization are essential to achieve this goal
with global data sharing at its core.
Key messages and academic research initiatives reported at the
Global ARO Council Workshop (held in Austin, TX, in November
2017) are summarized herein. From participants in the November
2017 Global ARO Network Workshop, projects related to a global
learning health system (LHS) in Asia (Japan, Taiwan, Singapore, and
Korea), Europe, and the United States are described from the perspec-
tives of government, regulators, and AROs. Themes are explored in
further depth to make recommendations for potential pathways
towards global LHSs. Prof Norihiro Sato opened by emphasizing that
we can accelerate the cycle of an LHS through harmonization,
standardization, and global data sharing. The closing discussion
moderated by Professor Masanori Fukushima and Dr Chris Austin
further develops the laudable goals, approach, and future vision of
the Global ARO Council and provides emerging themes from the
workshop participants.2 | JAPAN AGENCY FOR MEDICAL
RESEARCH AND DEVELOPMENT
Dr Maruyama presented on what has been referred to as Japan's
National Institutes of Health (“NIH”). The Japan AMED resulted from
a Japan Revitalization Strategy launched in 2013 by Prime Minister
Shinzo Abe to accelerate the development of practical applications
of innovative medical technologies. The Headquarters for Healthcare
Policy (HHP) was organized to promote integrated medical research
and development from basic science to practical application and to
enhance economic growth and the quality of medical care by promot-
ing the creation and overseas expansion of new activities within
industry that relate to health care and medical care. Related efforts
focused on enhancing safety measures for drugs and medical devices
and establishing development and regulation of regenerative medical
products. These broad steps were based upon two key observations
and strategic goals within Japan: (1) the decreasing rate of births along
with an increasing overall life expectancy emphasized the need for
healthy longevity and (2) a disconnect between basic medical research
and clinical research needed to be addressed.
AMED was funded by reallocating funds from multiple existing
agencies. AMED now promotes translational and clinical research
through a number of collaborative initiatives. The Health and Medical
Strategy calls for Japan to conduct innovative medical research and
development from preclinical/basic science conducted by academia
through regulatory approvals of new therapies and to demonstrate
leadership in collaborative international research. They are keenly
interested in playing a leading role in building such systems,
supporting core centers and hospitals to collaborate in international
clinical research. They work with regulators, industry, and academia
to fund and promote global research to improve health care.3 | US NIH NATIONAL CENTER FOR
ADVANCING TRANSLATIONAL SCIENCES—
CATALYZING TRANSLATIONAL
INNOVATION
Dr Christopher Austin stated, in response to an opening comment
about music being “the orderly placement of silence between the
notes,” that we currently have noise and dissonance rather than
silence, in the United States. “We pay people to be dissonant and
inharmonious” through incentives that are inadvertently in the wrong
places. He commented that Japan has a different approach in that
TABLE 1 Harmonized regulatory guidelines by the International
Council on Harmonization (ICH)
Harmonized regulatory guidelines
SAFETY
Carcinogenicity Biotechnology products
Genotoxicity Pharmacology
Toxicokinetics,
pharmacokinetics
Immunotoxicology
Reproductive toxicology Nonclinical evaluation of cancer drugs
Toxicity testing Photosafety
EFFICACY
Clinical study reports Statistical principles for clinical trials
Dose‐response Evaluation by therapeutic category
Ethnic factors, special
populations
Risk benefit
Clinical trials Pharmacogenomics
QUALITY
Stability GMP
Analytical validation Pharmaceutical development
Impurities Quality risk management
Pharmacopeias Pharmaceutical quality systems
Biotechnology product
specifications
Manufacture of drug substances
MULTIDISCIPLINARY
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funding to be awarded.
The NIH National Center for Advancing Translational Sciences
(NCATS) has a mission to enhance the development, testing, and imple-
mentation of diagnostics and therapeutics across a wide range of human
diseases and conditions. Collaboration with other government agencies,
academia industry, and nonprofit organizations is essential for NCATS.
One of the NCATS initiatives is the Clinical and Translational Science
Awards (CTSA), which Dr Austin described. The NCATS CTSA Program
Hubs innovate locally and collaborate regionally and nationally in projects
such as informatics, training, streamlining processes, community engage-
ment, and understudied populations. Data sharing is essential to CTSA
success. Cross‐CTSA initiatives, such as the Trial Innovation Network
(TIN), solve systematic problems that limit the efficiency and effective-
ness of clinical translational science.
TheTIN leverages the expertise and experience across CTSA cen-
ters to develop resources and capabilities that can benefit all centers,
such as an institutional review board (IRB) reliance platform, electronic
health record (EHR)‐based patient recruitment methods, standard
master agreements, and contracts. These are intended to reduce time
spent on these activities such that more science can be performed.
Focus has been on encouraging innovative scientific hypotheses and
models, novel study designs, patient‐reported outcomes (PRO)
endpoints, and a “learning clinical research system.”
Specific research networks mentioned as examples of data sharing
were the Rare Diseases Clinical Research Network (RDCRN), the
Undiagnosed Disease Network (UDN), and the Patient‐Centered
Outcomes Research Network (PCORNet). These involve common data
center and patient advocacy groups. He also referenced the All of Us
program, which is in the process of recruiting one million patients, has
an extensible data platform, and is an example of personalized
medicine. Dr Austin stated that it seems there is agreement that
standards are important, but not on which standards to adopt.
A recent cross‐CTSANCATS grant award that deserves special men-
tion is for the creation of a Center for Data toHealth (CD2H), which is led
by Dr Melissa Haendel. Dr Haendel reported specifically on her work in
this area in a presentation that is summarized later in this article.
Dr Rob Califf (Food and Drug Administration [FDA] Commissioner
in 2016 and well‐respected academic researcher from Duke) has been
quoted as saying “Clinical trials in this country take too long, cost too
much, and too often don't give us the answers we need to take care of
our patients. Other than that, the system works great.” Even the time
from funding approval to study start can take 2 years, and a study can
take over 10 years. The inability to recruit patients actually affects a
large percentage of trials, while the length of time to recruit can make
the trial eventually irrelevant because the underlying basic science
may move more quickly. This results in unnecessary loss of patient
lives, along with investigator careers and information that could
improve health, thus delaying the advancement of medicine and LHSs.
MedDRA terminology Common technical document (CTD)
and electronic CTD
Electronic standards Drug dictionaries: Standards and data
elements
Nonclinical safety reports Gene therapy genotoxic impurities
https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/ucm065004.htm.4 | US FOOD AND DRUG ADMINISTRATION
Dr Eileen Navarro spoke about the value of harmonization and
standards for FDA. Global clinical research studies are important,and harmonization can reduce timelines and costs for such trials.1
Global harmonization efforts such as those of the International
Council on Harmonization (ICH)2 have involved global regulators
and the regulated industry for many years. There are now harmo-
nized global guidelines that encompass many aspects of research,
including protocol development, statistical analysis, and an electronic
common technical document (eCTD) for regulatory submissions. One
example of an ICH product that has been harmonized by the United
States, Europe, and Japan is “Guidance for Industry: Providing
Regulatory Submissions in Electronic Format—Certain Human
Pharmaceutical Product Applications and Related Submissions Using
the eCTD Specifications.”3 The use of the MedDRA4 terminology
coding system for adverse events in clinical research has also been
agreed by the United States, Europe, and Japan through the ICH. See
Table 1 for other harmonized guidelines developed by ICH that are
referenced globally for regulated clinical research programs for
development of new therapies.
Dr Navarro used the analogy of shipping containers to illustrate
the value of standards for regulators. The shipping container, a simple
steel box, has a standard size that can be loaded onto semis, ships, and
planes. This has revolutionized shipping, making it “the biggest enabler
of globalisation.”5 The shipping container (a simple steel box 8 ft. wide,
8 ft. 6 in. high, and 40 ft. long) can be loaded onto a semitruck, a train,
4 of 10 FUKUSHIMA ET AL.a ship, and/or a plane and moved readily around the globe using these
different forms of transportation. This is a lesson for data sharing.
A sharing environment can streamline global research. Examples
provided are the common protocol template (CPT). Developed by an
FDA/NIH team6,7 concurrently with the TransCelerate CPT8 initiative,
these two templates have now been harmonized such that they apply
for industry/regulated trials as well as for academic/NIH trials. Proto-
col standardization is a key opportunity to being able to plan for
required standards downstream. The protocol elements comprising
the study design (ie, epochs, arms, and elements) are all required for
regulatory submissions so that the reviewers can have the necessary
context to comprehend the associated research results. This standard
template has been key in ensuring that key endpoints are aligned with
protocol objectives and provides an opportunity to critically review
essential data requirements, the statistical analysis plan, and integrity
of the study design. IRBs/ethics committees welcome protocols in
standard formats to facilitate their reviews and to ensure that the
necessary protocol components are addressed. This template is now
being “technology‐enabled” to facilitate reuse of components for trial
registration (ct.gov, WHO ICTRP, and EudraCT), in the analysis plan
and in the clinical study report or publication and results sharing.
“Content/metadata sharing” complements data sharing and facilitates
interpretation of the data.
Dr Navarro listed five core reasons on why standards matter:
Standards (1) bridge the evidence spectrum, (2) facilitate transparent
research, (3) facilitate efficient reviews, (4) facilitate data reuse, and
(5) matter to patients. A number of examples were discussed, including
the importance of being able to answer questions such as whether a
drug has varied effects on individuals in differently populations
(ie, women, men, children, or various races).9 She emphasized that
nonproprietary data standards encourage innovation. FDA now
maintains a Data Standards Catalog10 indicating standards they expect
to be employed for regulatory submissions to the US FDA for new
product approvals. Japan's analogous regulatory authority (PMDA)
also provides similar resources that are largely aligned with FDA on
the selection of and requirements around standards. Europe's EMA
does not yet require that the data be included in eSubmissions;
however, they are aligned on requirements around trial registration
and related protocol metadata.
Mitra Rocca of FDA spoke on the topic of RWD. RWD includes
“data derived from electronic health records, claims and billing data,
data from product and disease registries, patient‐generated data,
including in home‐use settings, and data gathered from other sources
that can inform on health status such as mobile devices.” Real‐world
evidence (RWE) is “the clinical evidence regarding the usage and
potential benefits or risks of a medical product derived from analysis
of RWD.”11 The FDA wishes to maximize the opportunities to incor-
porate data/evidence from settings that more closely reflect clinical
practice into the regulatory decision‐making process. Additional goals
are to increase population diversity and to improve efficiencies such
as identification of patients/populations and reduction of data reentry
or transcription, which is time‐consuming and negatively impacts data
quality. There are expectations in the 21st Century Cures Act in the
United States for FDA to establish a program to evaluate the use of
RWD to generate evidence. Global initiatives for organizations suchas AMED, Europe's Innovative Medicines Initiative (IMI), and the
ARO Council also reflect their interest in such objectives.
One project that is designed to explore the use of RWE derived
from delivery of health care in routine clinical settings is a Common
Data Model (CDM) Harmonization project funded by the PCOR Trust
Fund and led by Ms Rocca of FDA. This project will harmonize varying
CDMs (ie, Observational Medical Outcomes Partnership [OMOP]/
ODHSI, PCORNet, Sentinel, and Informatics for Integrating Biology
with the Bedside [i2b2]) with the Biomedical Research Integrated
Domain Group (BRIDG) model. The BRIDG model will serve as the
intermediary model; it is a global Clinical Data Interchange Standards
Consortium (CDISC), Health Level Seven (HL7), and International
Standards Organization (ISO) standard with the broad scope of
protocol‐driven research, including genomic data. The goal is to build
a data infrastructure for conducting PCOR using RWD/observational
data derived from the delivery of health care in routine clinical set-
tings. This will be achieved by developing and applying an automated
extract, transform, and load (ETL) process to harmonize several CDMs
with each other, leveraging open standards and controlled terminolo-
gies to advance PCOR (Figure below). The CDM Harmonization
project Use Case will be a pharmacovigilance assessment in the area
of oncology. Testing this Use Case will be a number of different data
partners, including AROs that have spent time and resources changing
data into different formats to accommodate the various networks that
have developed varying CDMs rather than using an existing standard.
The long‐term goals for this project are to
1. leverage the developed infrastructure to address additional use
cases;
2. share the developed methods, tools, and resources with inter-
ested stakeholders;
3. enhance regulatory decisions by providing FDA reviewers with
access to a larger network of RWD data; and
4. enable a set of standard data representations that can be used to
define relevant data models for an LHS.5 | EUROPEAN CLINICAL RESEARCH
INFRASTRUCTURE NETWORK
Dr Jacques Demotes, Director of the European Clinical Research Infra-
structure Network (ECRIN), presented on the ECRIN Data Center
Certification process, the Clinical Research Initiative for Global Health
(CRIGH), and the Consensus Document on Principles of Sharing
Individual Patient Data from Clinical Trials.12 ECRIN is a not‐for‐profit
intergovernmental organization in Europe that supports the conduct
of multinational clinical trials. ECRIN has spearheaded numerous
projects within Europe designed to build infrastructure for clinical
research. They have developed a set of criteria, including 129 require-
ments, to certify data centers and have conducted such certifications,
including in Asia and Africa as well as Europe. CRIGH includes projects
in the areas of (1) infrastructure and funding, (2) global core
FUKUSHIMA ET AL. 5 of 10competencies, (3) research ethics, (4) patient involvement, (5) compar-
ative effectiveness research, and (6) regulatory awareness.
One of the recent efforts of ECRIN involved a multiyear project to
build global consensus around a set of 10 data sharing principles
with associated specific recommendations. The resulting consensus
document was published in December 2017 and covers this topic in
more depth than prior efforts have dared to address. ECRIN is a core
supporter and facilitator of the ARO Council's activities. Additional
ECRIN activities are detailed on their website.136 | GLOBAL AROS
The remainder of the Workshop was dedicated to learning more about
activities within AROs and research institutes, based in Asia and
across the United States, that could align with the ARO Council's goals
and promote global expansion of LHSs. Three areas emphasized were
(1) supporting academic and pharma‐sponsored research (infrastruc-
ture, modernization, and the research enterprise); (2) data sharing
(methods, tools/platforms, registries, and data commons); and (3)
standards and tools to bridge the chasm between basic research and
clinical research.
From Asia, presentations by Dr Chung Y. Hsu from China Medical
University Hospital (Taiwan), Dr Ueng‐Cheng Yang from National
Yang‐Ming University (Taiwan), Shu Ling Lee from Singapore Clinical
Research Institute (SCRI), Dr In‐Jin Jang from Seoul National
University Hospital (Korea), and Dr Norihiro Sato a vice president of
ARO Council from Hokkaido University (Japan) were delivered.
Dr Chung Y. Hsu described the Taiwan Stroke Registry (TSR), a
stroke research network, the Taiwan Clinical Trial Consortium for
Stroke, and the Stroke Biosignature Project. TSR has network of 60
hospitals in Taiwan, and the consortium is contributing to improveFIGURE 1 The Asia Academic Research Organization (ARO) Networkthe effect of preventive measures and the development of safer and
more effective therapeutic strategies. TSR also takes the advantages
of sophisticated big data analytics based on the big database from
National Health Insurance covering more than 99% of the population
in Taiwan.
Dr Ueng‐Cheng Yang also presented their efforts that have been
made to harmonize and standardize their operation to facilitate
multicentered trials by using Clinical Informatics and Management
System (CIMS) that was developed at NIH and improved in Taiwan.
He also spoke about their preparation of obtaining accreditation of
Data Center by ECRIN to improve data quality.
Shu Ling Lee presented their challenges to adopt and meet CDISC
standard in SCRI, which is the only and national ARO in Singapore.
SCRI and TRI are providing similar clinical research services in their
respective countries.
Dr In‐Jin Jang presented approaches of Seoul National University
Hospital such as adopting CDISC standards, preparing ECRIN Data
Center Certification to be obtained in 2019, and facilitating
investigator‐initiated trials to enhance the clinical research capability
as a leading hospital in clinical research in Korea.
Dr Norihiro Sato presented the strategy for global clinical trials by
Japan ARO Council as a vice president. History of national TR projects
for medical innovation and achievement by utilizing ARO Network in
Japan was also described. The Asian ARO Network was constructed
as the first phase of the formation of multinational network towards
the common goal as Figure 1 shows.
The Asia ARO Network has been formed among Korea, Taiwan,
Singapore, and Japan and is cooperatively seeking to realize this com-
mon goal. CDISC standards implementation in Asian ARO Network
was agreed among Asian institutes. Likewise, the ARO Network is
targeting to be ECRIN certified data center to promote standardiza-
tion and organize multinational clinical trials.
6 of 10 FUKUSHIMA ET AL.Concurrently, ARO Council is focusing to form disease‐specific
consortia in global countries (Figure 2). For each specific disease, a
registry has been constructed, often in each country, or sometimes
collaboratively. Registries should be combined, which is believed not
to be a difficult task. An initial step will be catalog creation of the reg-
istry to enable sharing of the greatest common measures of those data
that have been collected across the registries. For such data sharing, a
good leading example, which has already taken a concrete approach
towards standardization and harmonization, is the Alzheimer's Disease
Neuroimaging Initiative (ADNI) study, for which there has been
excellent cooperation among research groups.14
The next milestone will be to initiate clinical trials concurrently
and to obtain regulatory approvals simultaneously for academia‐
originated candidate products within 5 years. Plans are in progress
to expand this framework to the United States and EU. This Novem-
ber ARO Network meeting in the United States was a first step in
the direction of the vision to conduct global clinical trials and
concurrent regulatory approvals of academia‐developed innovation
within 10 years.
Topics that emanated from representatives of US academic
institutions and related clinical research endeavors centered around
(1) infrastructure, modernization, and development of a research
enterprise to support various types of research, including academic
and biopharmaceutical and government research; (2) data sharing
and promoting standardization and harmonization to enable effective
aggregation and interpretation of data; (3) planning for data sharing
from the start; and (4) developing resources and common data
repositories to support cross‐organizational research.
Presenters from AROs and related research organizations based in
the United States included Dr Daniel Ford (Johns Hopkins), Marianne
Chase (Neurological Clinical Research Institute [NCRI], Massachusetts
General Hospital/Harvard), Dr Erika Augustine (University ofFIGURE 2 Academic Research Organization (ARO) Network focus on disRochester), Dr Jonathan Silverstein (University of Pittsburgh), John
Speakman (New York University), Dr Matthew Cowperthwaite and
Dr Chris Webb (University of Texas Dell Medical School), Dr Ida Sim
(University of California, San Francisco, and Vivli), Dr Sam
Volchenboum (University of Chicago), and Dr Melissa Haendel
(Oregon Health & Science University).
Dr Daniel Ford of Johns Hopkins spoke about the need for
academic medical centers involved in research to be able to support
principal investigators who are involved (both at sites and at the
university) in research that is commercially, not‐for‐profit, or federally
funded. Dr Ford emphasized that, despite the progress made in using
EHR data for research, there will not be efficiencies in accessing data
for clinical research unless there is a similar infrastructure across the
various studies. Without a common way to access research informa-
tion, study start‐up is delayed, start‐up costs are higher, additional
training is needed, and error rates are higher. In addition to the need
for standardization and infrastructure harmonization, it is important
to make the effort to integrate research into usual clinical practices
while developing efficient and safe methods to access and share data
in multicenter research studies.
John Speakman (New York University Langone Medical Center)
concurred with the need for the central IT function of the medical cen-
ter to support multiple different medical departments in their research
interests and to ensure “pharma‐grade” quality and regulatory compli-
ance. These include study design, setup and management, data man-
agement (large scale and traditional), and data analytics. The NYU
Langone Research IT group is well on their way to implementing the
aspiration for their DataCore services. They have employed CDISC
experts to focus on the standardization and harmonization activities.
Specifically, the aspirations for the NYU DataCore Clinical Research
Data Management include standardization of data format (ie, CDISC),
standardization of reports, DSMC reports, a case report form library,ease‐specific registries to enable multinational clinical trials
FUKUSHIMA ET AL. 7 of 10centralized oversight (administration) of study databases, expert back‐
office support, 21CFR11 compliance, process flow for IT study build,
and technology (including electronic data capture [EDC] and EHR
integration).
Marianne Chase, from the NCRI/Massachusetts General
Hospital,15 Harvard, presented on the academic leadership, methods,
capabilities, and technology tools that have been developed and are
being employed by the NCRI, which supports both the NIH‐funded
NeuroNEXT Network (25 sites in the United States specializing in
neurology) and the NEALS Network (119 sites around the world
involved in research on ALS). Tools include platforms that are
compliant with regulations and enable EDC, regulatory document
management, and clinical trial management in addition to PRO. NCRI
also has a biorepository and registries for these therapeutic areas.
Dr Matthew Cowperthwaite spoke about research within St.
David's HealthCare, which is based in Austin, TX, operates eight acute
care hospitals and more than 100 clinical sites acrossTexas. St. David's
is a partnership between Hospital Corporation of America (HCA)
Healthcare, the largest hospital network in the United States; St.
David's Foundation, which is the largest charitable not‐for‐profit foun-
dation in Central Texas; and the Georgetown Health Foundation. St.
David's maintains large clinical trials programs in cardiology (electro-
physiology and interventional cardiology) and neuroscience. Across
the HCA enterprise, research strengths include oncology, cardiology,
neuroscience, and infection prevention. Sarah Cannon, the Global
Cancer Institute of HCA, acts as the Site Management Organization
(SMO) for oncology research sites and physicians in the United States
and the United Kingdom. Sarah Cannon also operates a large Clinical
Research Organization (CRO) to run studies for industry partners
and also functions as an SMO for cardiology research in certain HCA
divisions. HCA is highly focused on data standardization (normalizing
data from 177 hospitals in an enterprise data warehouse), building
and aligning collaborative networks of physicians and executive
leaders, and improving processes such as communication channels,
study start‐up processes, corporate policies, and QA programs. HCA
is a Sentinel Data Partner on the CDM Harmonization project
described previously.
Dr Erika Augustine described the University of Rochester's Center
for Health and Technology (CHeT), which has three core areas of
focus: Clinical Trials Coordinating Center, Material Science Services
Unit, and Clinical Research Innovation. They partner with academic
groups, private groups, and industry sponsors. Examples of innovative
tools they have employed include wearable sensors, smartphones,
mobile apps, telemedicine, and virtual studies. Activities they are doing
to modernize the way clinical trials are implemented include virtual
visits, objective measures of disease including wearables and apps,
disease modeling, data visualization, data‐driven site selection, and
risk‐based monitoring. CHeT is experienced in conducting and
participating in collaborative clinical research, has developed
approved regulatory compounds, and focuses on programs that bring
stakeholders together to advance change.
Dr Chris Webb leads the research strategy for the new Dell Med-
ical School at the University of Texas at Austin, which has a unique
opportunity to change the academic health environment to better
serve society, as a new medical school associated with a majoruniversity. Its first class of medical students matriculated in 2016.
The vision, mission, and tagline (“Rethink Everything”) speak to this
opportunity. Dr Webb also spoke about the desire to incorporate
research into “everything” and that every patient visit should be a
research visit. There is keen interest within this new medical school
in building an LHS as evidenced by the hiring of an experienced indi-
vidual to lead this initiative. The mission is to revolution how people
get and stay healthy by improving health in our community as a model
for the nation, evolving new models of person‐centered, multidisci-
plinary care that reward value, advancing the pace of research and
innovation to improve health, educating leaders who transform health
care, and redesigning the academic health environment to better serve
society.
Dr Jonathan Silverstein from the University of Pittsburgh further
described an LHS as one that gets the right care to people when they
need it and then captures the results for improvement. The Institute of
Medicine (now the National Academy of Medicine) held a series of
workshops on the Digital Infrastructure for the Learning Health
System. “We seek the development of a learning health system that
is designed to generate and apply the best evidence for the collabora-
tive healthcare choices of each patient and provider; to drive the
process of discovery as a natural outgrowth of patient care; and to
ensure innovation, quality, safety, and value in health care” (US
National Academies of Medicine/Institute of Medicine).16
Dr Silverstein went further to discuss service‐oriented science17
and data science as a service, which led to requirements for a Data
Commons18 and the definition of a new role, a Clinical Research Infor-
mation Officer (CRIO), a role that is “critical to managing the interface
between systems and research needs and can provide dedicated lead-
ership and governance models charged with designing, deploying and
leveraging various information resources to advance research.”19 Dr
Silverstein then described a number of related projects ongoing with
the Research Informatics Office at University of Pittsburgh. These
include building a research data warehouse and a cohort finder using
EHR data, participating in the NIH/NCATS ACT Project (focused on
the accrual of patients to clinical trials); NIH All of Us; PCORI‐funded
research; the TIES Cancer Research Network (TCRN) oncology project
to share tissues and data using tools based on natural language pro-
cessing; and the Pittsburgh Genome Resource Repository at the Uni-
versity of Pittsburgh and Pittsburgh Supercomputing Center (PSC),
which provides data management and computing infrastructure to
support use of national genome data resources for personalized med-
icine research. Dr Silverstein's presentation began by showing the
relationship between obtaining new data and being able to reuse
existing data based upon whether data are structured or unstructured.
This challenge, summarized as collecting data consistently and
completely, is at the core of being able to more efficiently use
information/data to support LHSs.
Dr Ida Sim of the University of California, San Francisco, has expe-
rience in creating tools to search publications using structured data.
During this workshop, she described Vivli, a new nonprofit with a mis-
sion to “promote, coordinate, and facilitate analysis across clinical
research data through the creation and implementation of a sustain-
able global data‐sharing enterprise.”20 Vivli consists of a user‐friendly,
secure, state‐of‐the‐art cloud‐based data sharing and analytics
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from any disease, country, sponsor, funder, or investigator in
conducting open searches, with robust security and modern tools
and technologies. Vivli makes use of the Cochrane ontology21 based
upon PICO (Population, Intervention/Comparison, Outcomes) and
provides a place for clinical research data to be shared if there is not
already and agreed location for such sharing. The objective is to cata-
lyze the evolution of clinical research towards and effective culture of
data sharing and data reuse.
A diagram of the Vivli platform is shown in Figure 3.
Dr Sam Volchenboum of the University of Chicago and its Center
for Research Informatics spoke of his experience developing a Cancer
Data Commons with a Call to Action to have harmonized data
leading to shared data, samples, and data with universal identifiers,
envisioning data collection, and sharing at all stages of care, with an
overarching goal of “all data from all patients at all times.” Building a
Data Commons addresses current issues, including the fact that
analyzing big data is time‐consuming and costly and does not always
provide useful results due to lack of standards. In addition, having
phenotype/clinical data with universal identifiers harmonized into an
easily‐accessible Commons facilitates linking to genomic data and
enriching the ability of researchers to utilize this important informa-
tion. Based upon experience in creating a Data Commons for pediatric
cancer, Dr Volchenboum shared a step‐wise paradigm he has
developed for this purpose.22
Dr Melissa Haendel of the Oregon Health & Science University
described the challenge in biomedicine around integrating knowledge
across domains and disciplines, especially basic research and clinical
care. This integration will inform clinical diagnoses, especially in cases
of rare diseases when the genotype and phenotype information of a
new patient can be compared with other known cases. There is a current
gap (referred to by Dr Christopher Chute as the “chasm of semantic
despair”) between basic science information and clinical information.
TheMonarch Initiative23,24 is a global, translational consortium that
leverages a large body of structured and integrated genetic information
to provide sophisticated algorithms for phenotype comparison within
and across species. Monarch provides computational tools, interactive
visualization, and bioinformatics analyses based upon multiple
information sources to shorten the information exchange path for
clinicians and researchers. The ultimate goal is to advance personalized
medicine.FIGURE 3 The Vivli ProcessTo address the need to bridge resources and activities such as
what Monarch provides and achieves with clinical care and health
data, NIH/NCATS has awarded a grant to Dr Haendel as the lead
investigator of a collaborative opportunity to create a new CD2H as
a cross‐CTSA initiative.25 The priorities for the new CD2H will to
support a “vibrant and evolving informatics ecosystem,” including• support and enhancement of a collaborative informatics community;
• development of Good Data Practices (GDP);
• promotion of software standards for interoperability;
• growth of collaborative innovation across informatics tools,
methods, and processes;
• advancement of cutting edge biomedical research informatics;
• data science education for CTSA Program researchers; and
• novel methods and tools for the evaluation of the impact of these
activities to enhance health care through data and informatics.
Dr Haendel also spoke about a number of ongoing projects and ini-
tiatives that will be leveraged to achieve the goals of the CD2H.
These include the Human Phenotype Ontology (HPO),26,27 which
captures symptoms and phenotypic findings to assist in making
computational phenotype comparisons with known diseases and
patients; diagnostic tools such as Exomiser28; and the Global Alliance
for Genomics and Health (GA4GH) Matchmaker Exchange. She
described the GA4GH “phenopackets” exchange format, which enables
data sharing of computable phenotype information. She indicated the
value of collaborating with international organizations such as the ARO
Network to catalyze a “vital translational community focused on the
collaborative application of integrated genotype and phenotype data to
aid human disease discovery and diagnosis.”
The CD2H project led by Dr Haendel includes other collaborators.
Named in the award are Kristi Holmes, PhD, Northwestern University;
Sean Mooney, PhD, University of Washington; Christopher Chute, MD,
Johns Hopkins University School of Medicine; and John Wilbanks, Sage
Bionetworks. The Data to Health Coordination Center grant, which
supports the new center, has been awarded to these institutions,
together with The Scripps Research Institute, Washington University in
St. Louis, The University of Iowa, and The Jackson Laboratory. They will
all work with other centers that have received NIH/NCATS CTSA.
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Discussions at the end of theGlobal ARONetworkWorkshop of Novem-
ber 2017 were led by Dr Chris Austin (US NIH/NCATS) and DrMasanori
Fukushima (Japan's Translational Research Informatics Center, Founda-
tion for Biomedical Research and Innovation). The focus was on the
primary roadblocks to streamlining global clinical research projects.
The participants listed the need for infrastructure investment,
perseverance, metathesaurus/standards, convergence, and core
expertise. Participants voiced their concern that this topic needs
further discussion and agreement on how to alleviate the barriers.
The achievement of true LHSs will require such discussion, explora-
tion, consensus building, and funding with the necessary contingen-
cies that this be tied to data sharing and other activities that are
not currently incentivized through government funded research, at
least not in the United States. Lessons can be gleaned from the
IMI in the EU, ECRIN, AMED, and the ARO Council in Europe
and Japan. The recent CORBEL Consensus Document on data shar-
ing and reuse from Europe will also serve as an excellent resource.
Dr Fukushima stressed in his closing remarks the need for AROs
around the world to work together, to harmonize and standardize and
to ensure that data are housed in data centers that meet certification
criteria. The goal towards long, healthy lives and towards treating dis-
eases relies on global data sharing. Participants in theGlobal AROCouncil
Workshop expressed interest in continuing to be included in further dis-
cussions to facilitate the progress towards global research and true LHSs.8 | EMERGING THEMES AND
RECOMMENDATIONS FOR REALIZING THE
GLOBAL ARO NETWORK VISION
Themes from the previous Global ARO Network Workshops have
included Harmonization and Standardization, New Paradigm for
Medical Science based on Data Sharing, and RWD and Disruptive
Innovation. These broad themes resonated throughout the presen-
tations. From a tactical perspective, an action plan has now been
published by the Learning Health Community29 to identify key
areas that need focus in order to realize an LHS. Principles and rec-
ommendations are available for Data Sharing in the CORBEL Con-
sensus Document.
Emerging themes and recommendations emanating from this spe-
cific research‐focused ARO Network Workshop that could improve
research processes and serve to better connect research with practice
could be summarized as follows.
• Plan research with the end in mind and have a robust infrastruc-
ture, potentially preceding global clinical research studies with
disease‐specific registries for sharing data.
Understanding the objectives of the research, for example, what
you would like to have in the results tables of a publication or on
the label of a new therapy, the statistical requirements, and how the
data should be formatted and what the key endpoints are will help
in planning the study before it starts. Having an infrastructure thatsupports this planning will facilitate implementation. An initial step
that is proving to be very important for the Asia ARO Network, prior
to initiating global clinical trials, is to create a registry and begin shar-
ing data in this manner. Harmonization and standards can emerge
when registries are combined and/or data are shared through such
means; these can then be applied to the design and data collection
for clinical research studies.
• Globally harmonize and encourage adoption of common standards.
The more broadly adopted standards (for data, metadata, models,
and terminology), the easier the sharing of data and communication of
meaning along with that data. Starting a new standard (especially if it
is a one‐off or proprietary standard) exacerbates the issues we cur-
rently face, creating inefficiencies and increasing costs and resource
needs. New standards should be extensions of existing foundational
standards and not redundant standards that have already been
developed.
• Integrate from beginning to end—from basic science to clinical
research to health care.
This is the premise behind translational medicine, from “bench to
bedside,” precision medicine, the CD2H initiative, and a number of
CTSA initiatives. A number of areas still need to be addressed for this
to become a global reality, but acknowledging its value and funding
initiatives in this area is an important step.
• Address privacy, confidentiality, legal, and other issues around
data sharing.
Recommendations in the CORBEL Consensus Document have
paved the way for such issues to be addressed; however, they
(especially legal issues) still use excessive time, energy, and resources
that could be dedicated to research.
• Implement new technologies that are innovative and standards‐
based.
There is no shortage of new technologies available that could be
applied to research. FDA is encouraging their use. However, many still
need validation and a way to readily share data in standard formats
before they can be widely adopted and applied.
• Accommodate RWD to accumulate RWE.
As with new technologies, the use of RWD for research remains a
challenge. FDA has issued Guidance on this topic, and the 21st
Century Cures Act calls for its use. However, the variation and
implementation specificity of EHRs and moving target of health care
standards around the world have been a significant barrier to
obtaining high‐quality RWD for research purposes.
• Improve and accelerate the sharing process from research to
improve clinical care decisions.
10 of 10 FUKUSHIMA ET AL.Patients who participate in research studies do so not only for
their own benefit but also for the greater good. They expect their data
to be used wisely and for learnings to be shared as quickly as possible,
not to be trapped in a research silo or lost due to lack of quality or
standards. Computable knowledge is essential as is data sharing.
Accelerating learning health cycles forms the basis for LHSs.
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